Cytotoxicity on Human Cancer Cells of Ophidiacerebrosides Isolated from the African Starfish Narcissia canariensis

Marine Drugs

Fereshteh Farokhi¹  Gaetane Wielgosz-Collin¹  Monique Clement²  Jean-Michel Kornprobst¹ 

[1] Research Group Sea, Molecules and Health EA 2160, College of Pharmacy, University of Nantes, 1 rue Gaston Veil, BP 53508, F-44035 Nantes Cedex 01, France; E-Mails:;INSERM CRNA U892, 8 quai Moncousu, BP 70721, F-44007 Nantes Cedex, France; E-Mail:

关键词: glycosylceramides;    human cancer cell lines;    in vitro anticancerous activity;    Narcissia canariensis;    starfish;   

DOI  :  10.3390/md8122988

来源: mdpi

【 摘 要 】

The starfish Narcissia canariensis harvested from the coasts off Dakar, Senegal, was investigated for glycolipids (GL). This report deals with the isolation, characterization and biological activity of a fraction F13-3 separated from the GL mixture and selected according to its ability to inhibit KB cell proliferation after 72 hours of treatment. Firstly, a GL mixture F13 was obtained that accounted for 1.36% of starfish biomass (dry weight) and 0.36% of total lipids. The fraction F13-3 obtained from F13 contained three homologous GL identified as peracetylated derivatives on the basis of chemical and spectroscopic evidence. These contained a β-glucopyranoside as sugar head, a 9-methyl-branched 4,8,10-triunsaturated long-chain aminoalcohol as sphingoid base and amide-linked 2-hydroxy fatty acid chains. The majority (63%) had an amide-linked 2-hydroxydocosanoic acid chain and was identified as the ophidiacerebroside-C, firstly isolated from the starfish Ophidiaster ophidiamus. The minor components of F13-3 differed by one more or one less methylene group, and corresponded to ophidiacerebroside-B and -D. We found that F13-3 displayed an interesting cytotoxic activity over 24 hours on various adherent human cancerous cell lines (multiple myeloma, colorectal adenocarcinoma and glioblastoma multiforme) with an IC₅₀ of around 20 μM.

【 授权许可】

CC BY   
© 2010 by the authors; license MDPI, Basel, Switzerland.